Science

Psychotropics have a demonstrated therapeutic benefit with Very low abuse rates(1)

Tryptamine Drugs (Psychedelics, Hallucinogenics, Entheogens) are receiving international recognition for their potentially transformative therapeutic properties.

​

Tryptamines act on serotonin receptors, increase the concentration of dopamine and show indications of promoting neurogenesis and synaptogenesis.

​

Tryptamines are on the opposite end of the dependence spectrum compared to abused street drugs and pharmaceutical narcotics.

(1) Gable, R. S. (2006). Acute toxicity of drugs versus regulatory status. Drugs and society: US public policy, 149-62.

​

PSYBIO THERAPEUTICS
AND MIAMI UNIVERSITY:
SOLVING THE CHALLENGE OF 

CLINICAL SCALE PRODUCTION

​

Psilocybin was first purified from the Psilocybe mexicana mushroom by the Swiss chemist, Albert Hofmann, in 1958.

​

Current methods remain tedious and costly, involving numerous intermediate separation and purification steps beginning from 4-hydroxyindole (Shirota et al., 2003), and incurring an estimated cost of $2,000 per gram for pharmaceutical-grade psilocybin (Fricke et al., 2019).

​

Dr. J. Andrew Jones and Team at Miami University, have developed a platform technology and method to enable the large scale production of the natural product, psilocybin, it’s intermediates, and other molecules.

​

PsyBio Therapeutics has acquired the global exclusive rights, to the platform technology enabling rapid generation of cheaper, faster, and greener tryptamine medications with desirable properties.(1)(2)

1. Forward-looking statements are subject to various risks and assumptions. See “Cautionary Statement” and “Forward Looking Information” on page 2 of this presentation.

2. Subject to receipt of all necessary approvals, including as applicable, governmental authorities and the academic and scientific organizations with which PsyBio is working . There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain tryptamine and other analogues.

PATENT PENDING PROCESS

Patent pending process of using a recombinant prokaryotic host(1):

Adams A. M, Kaplan, N. K., Jones J. A., METHODS FOR THE PRODUCTION OF PSILOCYBIN AND INTERMIDATES AND SIDE PRODUCTS International Patent Application Serial No. PCT/US2020/051543 - PCT APPLICATION FILED 9.18.20

​

Genetic and fermentation optimization techniques resulted in highest product titer and yield reported to date upon bioreactor scaleup.

​

Initial data suggests E. coli produced psilocybin has a high degree of thermostability.

1. Adams AM, Kaplan NA, Wei Z, Brinton JD, Monnier CS, Enacopol AL, Ramelot TA, and Jones JA. "In vivo production of psilocybin in E. coli.“ Metabolic Engineering 56 (2019): 111-119

ADVANTAGES OVER
PUBLISHED METHODS

1. Adams et al. Metabolic engineering 56 (2019): 111-119.

2. Sherwood et al. Synthesis 52.05 (2020): 688-694.

3. Milne et al. Metabolic Engineering (2020).

4. Bigwood et al. Journal of ethnopharmacology 5.3 (1982): 287-291.

​

Future Opportunities(1)(2)

Developing Full Portfolio of Psychedelic Compounds

(1) Forward looking statements are subject to various risks and assumptions. See “Cautionary Statement” and “Forward Looking Information” on page 2 of this presentation.

(2) Subject to receipt of all necessary approvals, including as applicable, governmental authorities and the academic and scientific organizations with which PsyBio is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocybin, it’s intermediates, and other molecules.